No One Tracks Adherence

Rationale

This slide combines competitive positioning with moat defensibility. The table makes it immediately clear that no existing player tracks adherence — the column of "No" entries leading to Syntropy's "Yes" is the visual punch. The moat cards below reinforce three distinct defensibility mechanisms.

Talking Points

• "For Glico: you know these players. Noom is consumer-facing, Elo makes their own supplements, Viome is testing. None of them generate the data you need to prove YOUR products work. Syntropy is the only platform that gives brand partners evidence of product efficacy."
• "Look at this table. Noom — consumer app, no adherence. Elo — custom supplements, no adherence. Viome — testing, no adherence. Klaviyo — email marketing, no adherence. Recharge — subscription billing, no adherence. Syntropy — yes. We are the only one."
• "Recharge is the clearest contrast. They manage billing cycles — charge on day 30. We manage behavior — ship when the customer actually needs it. That is the difference between a billing tool and an intelligence platform. Over-ordering is the #1 reason customers cancel subscriptions. We eliminate it."
• "Four layers of defensibility. Proprietary methodology: PDC-derived, clinical grade. Consumer lock-in: daily check-ins that compound over time. Data network effects: more protocols create more data, which improves our AI, which attracts more partners. Usage-based subscription intelligence: no subscription platform knows whether the customer actually uses the product. We do."
• "The moat deepens with every brand: each protocol published, each consumer tracked, each data point collected makes the Health Graph more valuable and harder to replicate."
• Transition: "Let me show you what we are asking for and how it maps to milestones."

Anticipated QA

• Q: Can't Klaviyo add this?
  A: Klaviyo is messaging infrastructure. They send emails; they do not track whether customers take their supplements. Adding adherence tracking would require building a consumer-facing AI companion, a clinical measurement system, and a three-sided data layer. That is a different company.
• Q: What about Apple Health / Google Fit?
  A: They track steps and heart rate — hardware sensor data. We track protocol adherence — behavioral data specific to supplements and wellness products. Different data, different moat, complementary not competitive.
• Q: What if a big company just builds this?
  A: They could add basic tracking, but cannot replicate the Health Graph. Our competitive advantage is the combination of protocol-level adherence data, AI-powered consumer engagement, and three-sided marketplace dynamics. Different category entirely.

Sources

• Competitor funding: Noom ($600M+), Elo Health ($23M), Viome ($175M+), Klaviyo ($1.5B+), Recharge ($277M)
• PDC methodology: Pharmacy Quality Alliance, "PQA Adherence Measures" (adapted)
• Competitive landscape: desktop research of 50+ retention tools, wellness apps, and supplement platforms